ToleroGenics

Executive Summary

ToleroGenics is a Luxembourg-based biotech company founded in 2016, focused on developing novel tolerance-based immunotherapies for allergy and autoimmune diseases. The company leverages a proprietary technology platform aimed at curing rather than managing symptoms by reinstating the immune system's natural regulatory balance. As a public-private partnership with the Luxembourg Institute of Health (LIH), ToleroGenics operates at the intersection of academic research and commercial development, targeting significant unmet needs in immunology. The platform's approach has the potential to transform patient outcomes by offering durable tolerance, differentiating it from conventional immunosuppressive treatments. While still in early stages with no disclosed pipeline or funding details, the company's positioning in the European biotech ecosystem and its strategic partnership provide a foundation for growth. The conviction score reflects the inherent uncertainty of early-stage biotech, balanced by the promising therapeutic paradigm and institutional support.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept studies for lead candidate50% success
• Q3 2026Announcement of additional public or private funding round70% success
• TBDExpansion of research collaboration or licensing deal with LIH40% success